The pivotal clinical trial was designed to evaluate the effectiveness and safety of the RECELL System for soft tissue repair. Credit: Nephron / commons.wikimedia.org.

Avita Medical has announced that the pivotal clinical trial of its RECELL System for soft tissue repair has achieved the co-primary endpoints in updated data analysis.

The trial was designed to assess the RECELL System’s effectiveness and safety for soft tissue repair.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It included two co-primary endpoints; one had a hypothesis of superiority for donor skin-sparing while the other had a hypothesis of non-inferiority for healing.

The company stated that these endpoints were based on pairwise comparisons, where each participant in the study received treatment with the RECELL system as well as the standard of care treatment (control).

Findings from the study demonstrated that the RECELL system achieved statistically significant donor sparing over control (p<0.001) and non-inferiority for healing versus control (p<0.025).

These findings will support the company’s application for premarket approval (PMA) from the US Food and Drug Administration (FDA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AVITA Medical CEO Jim Corbett said: “These results reinforce the potential for RECELL to become a new standard of care for soft tissue repair.

“We look forward to sharing the soft tissue repair outcomes with the FDA via our PMA submission expected in December 2022.”

The RECELL System allows healthcare providers to produce a suspension of Spray-On Skin Cells using a small sample of the patient’s own skin to treat acute thermal burns.

It has been designed to be used at the point of care setting alone or with autografts depending on the depth of the burn injury.

AVITA Medical previously announced that the donor-sparing endpoint had achieved superiority.

The clinical trial of the RECELL System in soft tissue repair is backed with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.